The makers of more than a dozen prescription drugs covered by Medicare are seeing the first impacts of the Inflation Reduction Act (IRA) passed last …
CMS announces penalties on 27 prescription drugs, draft guidance on price controls Read More »
Biotechnology Innovation Organization (BIO) members Bristol Myers’, Pfizer’s, and AbbVie’s drugs “are likely to be among 10 big-selling medicines subject to U.S. price negotiations for …
U.S. drug price negotiation already affecting Bristol Myers, Pfizer, AbbVie Read More »
America’s largest integrated healthcare system, the Veterans Health Administration (VHA), will be providing coverage of LEQEMBI (lecanemab-irmb) “to veterans living with early stages of Alzheimer’s …
VHA is the first major insurer to cover Alzheimer’s drug LEQEMBI Read More »
In recent years, Artificial Intelligence (AI) has boomed in healthcare. AI is helping scientists obtain relevant data, accurately predict diseases at early stages, and help …
I am BIO Podcast: How AI and biotech can ‘run evolution at hyperspeed’ Read More »
On Friday, March 10, 2023, the United States Food and Drug Administration (FDA) approved Acadia Pharmaceuticals’ drug for genetic Rett syndrome, the company announced in …
FDA approves Acadia’s DAYBUE for the treatment of Rett syndrome Read More »
The 2024 budget proposal President Biden officially released yesterday is facing rocky ground ahead calling for, among other things, more innovation-killing drug price controls under …
Drug price controls in Biden’s proposed budget hurtful for patients, R&D Read More »
Experts told a House subcommittee Wednesday that China’s government coordinates a strategy to steal U.S. intellectual property – and the waiver of COVID IP would help …
Congress shines a light on China’s strategy to steal U.S. IP Read More »
The third anniversary of the COVID-19 pandemic on March 11 may feel to some like a relief as we transition into a post-COVID era. Yet, …
As the COVID pandemic turns 3, are we ready for the next one? Read More »
On March 8, 2023, during the first markup of health care bills this year, the Health Subcommittee of the House Energy and Commerce Committee deliberated …
Legislation potentially banning QALYs due to discrimination is under review Read More »
The breakthrough Alzheimer’s drug LEQEMBI could receive traditional Food and Drug Administration (FDA) approval later this year after receiving Accelerated Approval in January. Developed and …
Alzheimer’s drug LEQEMBI granted Priority Review for traditional approval Read More »
After surviving five mass extinctions, horseshoe crab populations are under pressure—but a regulatory change allowing drug makers to use a synthetic alternative to crabs’ blue …
Horseshoe crab population can be spared with regulatory change Read More »
